BioPharma « Terug naar discussie overzicht

quote:

psycho-pharma schreef:

Line-up: 1.64 - 1.66

quote:

SkySpam1 schreef:

[quote=psycho-pharma]
Line-up: 1.64 - 1.66
[/quote]

toch maar weinig beweging voorbeurs

quote:

Moraelin schreef:

Ask is laat en offer (of bid) is bied, man, weet je het nu nog niet. Weet ik ineens wie je bent.

[quote=bal gehak]
maar de meeste mensen denken ook niet echt na, daar heb ik me hier in het begin ook zo aan geergert. mensen die zeggen dat "bid" de "laat" is en "bied" het "offer" (en dan zeggen dat jij dom bent omdat je het niet snapt, haha schitterend). of dat er geen TA is toe te passen op biotech stocks;). daar moet je je even over heen zetten, tenminste als je hier niet al te gefrustreerd wilt worden. ik pas me ook aan, moet jij ook even doen ties dan zal je zien dat het je beter gaat. suc6!

ps visboon (lachen toch), dat plaatje van even eerder was super! met zo'n ierse boer met die tong, haha geniaal.

ik vind het hier leuk en kom graag, lachen hier!
[/quote]

quote:

M.A.D.W. schreef:

Jammer genoeg moet ik vandaag weg, net nu het een leuke dag wordt. Houden jullie INSM voor mij in de gaten. Doeiiiiiiiiiiiiii!

quote:

Do DD schreef:

Eerste en laatste post van mij voor deze hemelvaartsdag:

Re: The million dollar question Are we
by: doughcm 05/24/06 06:31 pm
Msg: 99257 of 99295

The pps is about where it was just before approval. I'm certainly not a market guru but my feeling is we will hang around here until any positive PR's: number of patients signed up, date of official launch, any further Phase trials planned or enrolling, etc. The announcement of launch will basically be a non event. Iplex has already been prescribed and shipped. The potentially big news will be if there are more prescriptions for Iplex than Increlex even before the "official" launch announcement. I have a hunch that is exactly what is happening. Don't put it past this management team to pull a little deceptive move along those lines. For those of you who think they are rank amateurs you will be proven wrong as time goes by. They have a business plan and they are doing exactly what they need to make this company a successful pharmaceutical company. Don't listen to the BS of those who bash this company. Time is on the side of INSM and they have a product with potentially wide-ranging applications. The initial approval was the toughest in the face of greater than normal odds. Further approvals for this company are in the offing. Rome wasn't built in a day. Partners for some of the further applications may be done, but that further dilutes revenues and if Iplex or rhIGFBP-3 prove themselves in the future like I believe they will, partners are not in the equation. With this science INSM is in the driver's seat, make no mistake about that. Do you think PFE, DNA, GENZ, or and of the other powerhouse pharmaceutical companies would love to have the science INSM has developed? You bet your sweet butt they would!
This is not a pump for INSM only the facts as I discern them through extensive DD and the help of the knowledge of many of the fine posters here and on I-Hub. May we all make money here. Short, long, bashers and pumpers.

tot morgen, E.
ps. Negeer aub treiteraars en andere zeurpieten, al kost het soms tandenknarsen, dan zijn ze 't snelst weer weg.